Coherus Oncology
CHRS
161 hedge funds and large institutions have $623M invested in Coherus Oncology in 2022 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 60 increasing their positions, 55 reducing their positions, and 31 closing their positions.
1.54% more ownership
Funds ownership: 99.55% → 101.09% (+1.5%)
9% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 55
6% less call options, than puts
Call options by funds: $1.18M | Put options by funds: $1.26M
7% less funds holding
Funds holding: 174 → 161 (-13)
16% less capital invested
Capital invested by funds: $744M → $623M (-$121M)
39% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$12.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$8.65M |
| 3 |
BlackRock
New York
|
+$8.44M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.52M |
| 5 |
JP Morgan Chase
New York
|
+$2.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$16M |
| 2 |
TLP
Tri Locum Partners
New York
|
-$6.12M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$4.88M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$3.88M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.68M |
CHRS Hedge Fund Activity: Q4 2022 in Review
161 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q4 2022, worth a combined $623M — down 16% from $744M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of CHRS and 19 opened new positions — a net loss of 12 holders — while 55 trimmed existing stakes and 60 added.
The largest buyer was State Street, adding an estimated $12.9M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $16M sold.
- 161 institutional investors held Coherus Oncology (CHRS) as of Q4 2022, down from 174 in Q3 2022.
- Funds reported $623M of Coherus Oncology stock for Q4 2022, down 16% quarter-over-quarter.
- 19 funds opened new Coherus Oncology positions in Q4 2022 and 31 closed out, a net change of -12 holders.
- The largest Coherus Oncology buyer in Q4 2022 was State Street, an estimated $12.9M added.
- The largest Coherus Oncology seller in Q4 2022 was Perceptive Advisors, an estimated $16M sold.
Based on aggregated 13F filings for Q4 2022.